23andMe's Stock Turns Lower After Company Posts Its Latest Quarterly Loss -- MarketWatch

Dow Jones11-12

23andMe Holding Co.'s stock $(ME)$ turned down early Tuesday, after the DNA-testing company reported fiscal second-quarter earnings, a day after it announced it would cut 40% of its workforce as part of a restructuring aimed at cutting costs. Sunnyvale, Calif.-based 23andMe said its net loss came to $59 million, narrower than the loss of $75 million posted in the year-earlier period. Revenue came to $44 million, down from $50 million a year ago. FactSet analysts no longer offer estimates for the company, which has seen it value plunge 98% from its 2021 peak to about $116 million as of Monday. In September, 23andMe's independent board members resigned en masse over a dispute with co-founder and Chief Executive Anne Wojcicki's plans to take the company private. Last month, it made moves to rebuild its board and underwent a 1-for-20 stock split for its Class A and B shares. The job cuts will impact about 200 employees. The stock rose more than 5% in after-hours trading Monday but was down 0.2% Tuesday. The stock has fallen 75% in the year to date, while the S&P 500 has gained 25.8%.

-Ciara Linnane

For more from MarketWatch: http://www.marketwatch.com/newsviewer

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

November 12, 2024 07:40 ET (12:40 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment